Publications + Posters

TNG348 is synergistic with PARP inhibitors in tumor models with elevated replication stress

Genome-wide drug anchor screens identify CAAP1 and AKAP17A as regulators of PRMT5 inhibitor sensitivity

Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitors

Experimental ‘loss-of function’ annotation of STK11 mutations with prognostic and therapeutic implications

TNG917 is a clinical-grade, potent and selective inhibitor of EHMT1/2 for the treatment of immune cold tumors